Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Profound Medical Corp. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.17
7.3
6.87
6.68
7.2
10.7
16.1
Cost of revenue
1.78
3.83
3.92
3.66
2.89
3.64
4.71
Gross profit
2.39
3.47
2.95
3.02
4.31
7.04
11.4
Research and development
9.4
9.91
15.3
14.7
14.4
17
20.6
Selling, general and administrative
18.5
23.1
32.1
Selling and marketing
3.35
4.48
3.86
Operating expenses
33
40.1
52.6
Operating income
-14.9
-18.9
-30.3
-32.1
-28.7
-33.1
-41.3
Interest expense
0.17
2.71
0.3
0.6
0.39
Other non-operating income
0.2
5.24
-1.06
Pre-tax income
-15.1
-21.6
-30.6
-28.4
-28.5
-27.8
-42.3
Income tax
0.15
0.05
0.11
0.29
-0.13
-0
0.25
Net income
-15.2
-21.6
-30.7
-28.7
-28.3
-27.8
-42.6
EBITDA
-13.4
-17.3
-28.4
-30.5
-27.9
-32.4
-40.9
EPS, basic
1.37
1.25
1.50
1.38
1.34
1.12
1.41
EPS, diluted
1.37
1.25
1.50
1.38
1.34
1.12
1.41
Shares, basic (weighted)
21.2
24.8
30.2
Shares, diluted (weighted)
21.2
24.8
30.2
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
14.8
83.9
67.2
46.5
26.2
54.9
59.7
Receivables
3.13
7.43
1.41
6.34
7.29
Inventory
3.67
5.33
7.41
7.94
6.99
5.8
8.24
Total current assets
22.8
97.7
77.1
62
41.9
69.1
76.1
Property, plant and equipment
0.53
0.86
0.79
0.9
0.91
0.43
0.7
Lease right-of-use assets
1.69
1.42
1.12
0.82
0.66
0.4
0.18
Goodwill
2.63
2.68
2.69
Intangible assets
2.41
1.9
1.44
0.68
0.49
0.26
0.14
Total assets
30.1
105
86.8
64.4
44
70.2
77.5
Accounts payable
0.87
1.32
1.56
Accrued liabilities
0.75
0.71
2.35
Deferred revenue
0.72
0.42
0.45
Short-term debt
2.1
1.74
Total current liabilities
8.22
4.81
4.16
4.19
6.37
6.57
6.08
Long-term debt
5
2.92
4.5
Lease liabilities
1.64
1.36
1.13
0.82
0.5
0.2
Other non-current liabilities
0.07
0.07
0.08
Total liabilities
15.7
7.25
6.16
12.4
12.7
9.81
11
Total debt
9.14
7.17
7.1
4.66
4.5
Paid-in capital
20.8
21.3
25.3
Retained earnings
-108
-130
-161
-189
-217
-245
-288
Other comprehensive income
5.57
2.74
5.03
Shareholders' equity
52.6
31.2
60.4
66.4
Total equity
14.4
97.4
80.6
52
31.2
60.4
66.4
Total liabilities and equity
30.1
105
86.8
64.4
44
70.2
77.5
Shares outstanding
21.4
30
36.3
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-15.2
-21.6
-30.7
-28.7
-28.3
-27.8
-42.6
Depreciation and amortization
1.51
1.54
1.88
1.6
0.73
0.71
0.37
Stock-based compensation
3.42
2.58
5.49
Deferred income tax
0.06
-0.15
0.02
Change in inventory
0.35
0.66
-2.82
Change in payables
1.35
0.82
0.38
Cash from operations
-15.1
-20.6
-22.4
-25.8
-22.6
-23.5
-38.2
Capital expenditures
-0.03
-0.18
Cash from investing
-0.19
-0.35
-0.59
-0.24
Debt issued
7.27
Debt repaid
-0.91
-2.56
-0.29
Stock issued
8.71
85.5
0.25
62.1
42.4
Cash from financing
6.6
87.4
5.95
7.03
1.76
54.7
41.1
Exchange rate effect
0.95
2.6
0.24
-1.87
0.53
Net change in cash
-8.64
66.5
-20.9
31.2
2.69
Free cash flow
-22.4
-38.4
Income taxes paid
0.16
0.25
0.13
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.76 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
71.8%
Gross profit / revenue.
Operating margin
-185.3%
Operating income / revenue.
EBITDA margin
-183.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-170.4%
Pre-tax income / revenue.
Net margin
-171.6%
Net income / revenue.
Operating cash flow margin
-189.1%
Cash from operations / revenue.
Return on equity (ROE)
-65.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-52.5%
Net income / average total assets.
Return on invested capital (ROIC)
-174.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
108.0%
Research and development expense / revenue.
SG&A / revenue
149.1%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
26.1%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
2.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
50.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
34.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
17.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
61.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
55.7%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
26.8%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y
25.9%
EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y
0.7%
Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y
2.4%
Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
10.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
8.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
10.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
6.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-5.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
22.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.46x
Current assets / current liabilities.
Quick ratio
4.20x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.20x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.09x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
7.2%
Total debt / total assets.
Liabilities / assets
20.2%
Total liabilities / total assets.
Net debt
-$33.8M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.53
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.99
Cash from operations / diluted weighted shares.
Book value per share
$1.36
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
11.0x
Market cap / revenue.
P/B
4.22x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.24x
Market cap / tangible book value, when positive.
EV/Sales
9.26x
Enterprise value / revenue.
Earnings yield
-15.6%
Net income / market cap (the inverse of P/E).
What was Profound Medical Corp.'s revenue in fiscal 2025?
Profound Medical Corp. reported revenue of $16.1M for fiscal 2025, 50.7% higher than the year before.
Was Profound Medical Corp. profitable in fiscal 2025?
No. It reported a net loss of $42.6M.
How much free cash flow did Profound Medical Corp. generate in fiscal 2025?
Cash from operations of $38.2M minus capital expenditures of $176.0K left free cash flow of -$38.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.